SARS-CoV-2 Infection and Alpha-Synucleinopathies: Potential Links and Underlying Mechanisms
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms252212079 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Joanna Agata Motyl und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hybrid Microbiosystems Engineering, Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences, Ks. Troj…. Hauptthemen laut MEDLINE: COVID-19, alpha-Synuclein, SARS-CoV-2, Synucleinopathies. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 236 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Centre, Poland, the National Science Centre, Poland.
Abstract (Originalsprache)
Alpha-synuclein (α-syn) is a 140-amino-acid, intrinsically disordered, soluble protein that is abundantly present in the brain. It plays a crucial role in maintaining cellular structures and organelle functions, particularly in supporting synaptic plasticity and regulating neurotransmitter turnover. However, for reasons not yet fully understood, α-syn can lose its physiological role and begin to aggregate. This altered α-syn disrupts dopaminergic transmission and causes both presynaptic and postsynaptic dysfunction, ultimately leading to cell death. A group of neurodegenerative diseases known as α-synucleinopathies is characterized by the intracellular accumulation of α-syn deposits in specific neuronal and glial cells within certain brain regions. In addition to Parkinson’s disease (PD), these conditions include dementia with Lewy bodies (DLBs), multiple system atrophy (MSA), pure autonomic failure (PAF), and REM sleep behavior disorder (RBD). Given that these disorders are associated with α-syn-related neuroinflammation—and considering that SARS-CoV-2 infection has been shown to affect the nervous system, with COVID-19 patients experiencing neurological symptoms—it has been proposed that COVID-19 may contribute to neurodegeneration in PD and other α-synucleinopathies by promoting α-syn misfolding and aggregation. In this review, we focus on whether SARS-CoV-2 could act as an environmental trigger that facilitates the onset or progression of α-synucleinopathies. Specifically, we present new evidence on the potential role of SARS-CoV-2 in modulating α-syn function and discuss the causal relationship between SARS-CoV-2 infection and the development of parkinsonism-like symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hybrid Microbiosystems Engineering, Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences, Ks. Trojdena 4 St., 02-109 Warsaw, Poland.
- Department of Biomedical Sciences, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszynski University, Wóycickiego 1/3, 01-938 Warsaw, Poland.
- Department of Cellular Signalling, Mossakowski Medical Research Institute, Polish Academy of Sciences, 02-106 Warsaw, Poland.
ORCID-Profile: Joanna Agata Motyl, Grzegorz Arkadiusz Czapski, Agata Adamczyk
Förderung
- National Science Centre, Poland
- the National Science Centre, Poland
Zitieren
APA
Motyl, J. A., Gromadzka, G., Czapski, G. A., & Adamczyk, A. (2024). SARS-CoV-2 Infection and Alpha-Synucleinopathies: Potential Links and Underlying Mechanisms. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252212079
Vancouver
Motyl JA, Gromadzka G, Czapski GA, Adamczyk A. SARS-CoV-2 Infection and Alpha-Synucleinopathies: Potential Links and Underlying Mechanisms. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252212079
BibTeX
@article{Motyl2024,
author = {Motyl, Joanna Agata and Gromadzka, Grażyna and Czapski, Grzegorz Arkadiusz and Adamczyk, Agata},
title = {SARS-CoV-2 Infection and Alpha-Synucleinopathies: Potential Links and Underlying Mechanisms},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms252212079}
}
EUVIMED